CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CXCL13 Promotes Proliferation of Mesangial Cells by Combination with CXCR5 in SLE
Authors
Keywords
-
Journal
Journal of Immunology Research
Volume 2016, Issue -, Pages 1-8
Publisher
Hindawi Limited
Online
2016-09-09
DOI
10.1155/2016/2063985
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Proliferation and Cytokine Production of Human Mesangial Cells Stimulated by Secretory IgA Isolated from Patients with IgA Nephropathy
- (2015) Yan Liang et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Arraying Autoantibodies in SLE – Lessons Learned
- (2015) L. Wang et al. CURRENT MOLECULAR MEDICINE
- Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis
- (2015) Yongyin Li et al. HEPATOLOGY
- CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia
- (2015) Boting Wu et al. Journal of Translational Medicine
- ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins
- (2015) Lixia Bai et al. MEDICAL ONCOLOGY
- Body Image Disturbances Have Impact on the Sexual Problems in Chinese Systemic Lupus Erythematosus Patients
- (2015) Biyu Shen et al. Journal of Immunology Research
- CXCL13 as a new biomarker of systemic lupus erythematosus and lupus nephritis - from bench to bedside?
- (2014) L. Schiffer et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pathogenetic role of glomerular CXCL13 expression in lupus nephritis
- (2014) K. Worthmann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
- (2014) J. De Azevedo Silva et al. CURRENT GENOMICS
- Lupus nephritis
- (2014) Georg Lorenz et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- The pathogenesis, diagnosis and treatment of lupus nephritis
- (2014) Noa Schwartz et al. CURRENT OPINION IN RHEUMATOLOGY
- Immunopathology of lupus nephritis
- (2014) Hans-Joachim Anders et al. Seminars in Immunopathology
- A Distinct Human CD4+ T Cell Subset That Secretes CXCL13 in Rheumatoid Synovium
- (2013) Shio Kobayashi et al. ARTHRITIS AND RHEUMATISM
- Thrombospondin-1 mediates oncogenic Ras–induced senescence in premalignant lung tumors
- (2013) Kwan-Hyuck Baek et al. JOURNAL OF CLINICAL INVESTIGATION
- Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria?
- (2013) GM Rezende et al. LUPUS
- Autoantibodies and Resident Renal Cells in the Pathogenesis of Lupus Nephritis: Getting to Know the Unknown
- (2012) Susan Yung et al. Clinical & Developmental Immunology
- Mesangial cell biology
- (2012) Hanna E. Abboud EXPERIMENTAL CELL RESEARCH
- CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation
- (2011) C. P. El-Haibi et al. CELL PROLIFERATION
- Elevated Production of B Cell Chemokine CXCL13 is Correlated with Systemic Lupus Erythematosus Disease Activity
- (2009) C. K. Wong et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation
- (2009) Serge A van de Pavert et al. NATURE IMMUNOLOGY
- B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE)
- (2009) L. Schiffer et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More